Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients with peripheral T-cell lymphomas. Duvelisib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem chłoniaka T-komórkowego obwodowego (tipos TFH lub PTCL-NOS)
- •Ukończenie pierwszej linii chemioterapii opartej na schemacie CHOP z całkowitą odpowiedzią w ciągu ostatnich 6 miesięcy
- •Niekwalifikujący się do przeszczepu lub odmowa przeszczepu komórek macierzystych
- •Liczba płytek krwi co najmniej 25 000/mm³
- •Hemoglobina co najmniej 8 g/dL
- •Liczba limfocytów CD4 co najmniej 50/mm³
- •Wyleczenie się z poprzednich efektów ubocznych leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
City of Hope Medical Center
Duarte, United States
Trial contact
Christina Poh
Christina Poh
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.